Laxmi Organic Industries Limited — PPTs, 21-05-2025: Investor Presentation

**1. Financial Highlights:**

Laxmi Organic reported consolidated revenue of INR 2,985 Cr for FY25, up 5% YoY. EBITDA grew 9% to INR 280 Cr with margins improving to 9.4%. However, Q4 saw a 9% revenue decline and EBITDA fell 34%, affected by one-time costs and a high base last year. PAT decreased 6% to INR 113 Cr due to higher depreciation and finance costs. Volumes rose 11% for the full year. Asset investments increased to INR 1,162 Cr, borrowings modestly rose to INR 63 Cr, and cash reserves remained stable.

**2. Strategic Initiatives & Growth Drivers:**

Capex of around INR 110 Cr is planned through FY28 for brownfield expansions at Dahej and Lote, boosting capacities in fluoro-intermediates and specialties. Environmental and factory approvals at Dahej are in place, and a new innovation center aims to strengthen R&D. The company targets doubling revenues and nearly tripling EBITDA by FY28 through new product launches, operational improvements, and fluorination tech scaling.

**3. Business Developments:**

Commercial operations started at the fluorospecialties plant in Lote, enabling product diversification. An MoU with Hitachi Energy will facilitate manufacturing of eco-friendly gases from next year. The Miteni acquisition and new derivatives for agro, pharma, and pigment sectors expand the specialties portfolio.

**4. Market Position & Competitive Advantage:**

Laxmi holds the top spot in India for ethyl acetate and ranks among the top three global players (excluding China) in Essentials and top five in Specialties. It leverages technology leadership, scale-based cost efficiencies, and a wide product range. The focus on customer service, operational consistency, and sustainability strengthens its competitive edge.

**5. Investor Implications:**

Volume traction, focused capex in high-margin segments, and strategic partnerships highlight positive growth potential. Fluorospecialties ramp-up and innovation investments are key value drivers. Execution timelines and market conditions pose risks, but a solid balance sheet and strong management support scalability and new revenue opportunities.